Academic literature on the topic 'TYROSINE KINASE ASSAY'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'TYROSINE KINASE ASSAY.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "TYROSINE KINASE ASSAY"
Tyner, Jeffrey W., Stephanie Willis, Michael W. N. Deininger, and Brian J. Druker. "RNAi Functional Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Acute Myeloid Leukemia Patients." Blood 110, no. 11 (November 16, 2007): 208. http://dx.doi.org/10.1182/blood.v110.11.208.208.
Full textPritz, Stephan, Gabriele Meder, Klaus Doering, Peter Drueckes, Julian Woelcke, Lorenz M. Mayr, and Ulrich Hassiepen. "A Fluorescence Lifetime-Based Assay for Abelson Kinase." Journal of Biomolecular Screening 16, no. 1 (December 8, 2010): 65–72. http://dx.doi.org/10.1177/1087057110385817.
Full textLebakken, Connie S., Hee Chol Kang, and Kurt W. Vogel. "A Fluorescence Lifetime–Based Binding Assay to Characterize Kinase Inhibitors." Journal of Biomolecular Screening 12, no. 6 (May 21, 2007): 828–41. http://dx.doi.org/10.1177/1087057107304480.
Full textKobayashi, Tomoko, Shun-Ichi Nakamura, and Hirohei Yamamura. "Cytosolic Protein-Tyrosine Kinase Activities in Various Rat Tissues." Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 26, no. 2 (March 1989): 164–68. http://dx.doi.org/10.1177/000456328902600213.
Full textTyner, Jeffrey W., Denise K. Walters, Stephanie G. Willis, Mary Luttropp, Jason Oost, Marc Loriaux, Heidi Erickson, et al. "RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia." Blood 111, no. 4 (February 15, 2008): 2238–45. http://dx.doi.org/10.1182/blood-2007-06-097253.
Full textWu, Jinzi J., Donna R. Yarwood, Quynhchi Pham, and Matthew A. Sills. "Identification of a High-Affinity Anti-Phosphoserine Antibody for the Development of a Homogeneous Fluorescence Polarization Assay of Protein Kinase C." Journal of Biomolecular Screening 5, no. 1 (February 2000): 23–30. http://dx.doi.org/10.1177/108705710000500106.
Full textTyner, Jeffrey W., Luke Fletcher, Wayne Yang, Stephen T. Oh, Jason R. Gotlib, Michael WN Deininger, Brian J. Druker, and Marc Loriaux. "Development of a Small-Molecule Inhibitor Screen to Rapidly Identify Key Signaling Pathways in Leukemogenesis." Blood 114, no. 22 (November 20, 2009): 708. http://dx.doi.org/10.1182/blood.v114.22.708.708.
Full textNakayama, Grace R., Michael P. Nova, and Zahra Parandoosh. "A Scintillating Microplate Assay for the Assessment of Protein Kinase Activity." Journal of Biomolecular Screening 3, no. 1 (February 1998): 43–48. http://dx.doi.org/10.1177/108705719800300106.
Full textBinns, Kathleen L., Paul P. Taylor, Frank Sicheri, Tony Pawson, and Sacha J. Holland. "Phosphorylation of Tyrosine Residues in the Kinase Domain and Juxtamembrane Region Regulates the Biological and Catalytic Activities of Eph Receptors." Molecular and Cellular Biology 20, no. 13 (July 1, 2000): 4791–805. http://dx.doi.org/10.1128/mcb.20.13.4791-4805.2000.
Full textRivard, N., G. Rydzewska, J. S. Lods, and J. Morisset. "Novel model of integration of signaling pathways in rat pancreatic acinar cells." American Journal of Physiology-Gastrointestinal and Liver Physiology 269, no. 3 (September 1, 1995): G352—G362. http://dx.doi.org/10.1152/ajpgi.1995.269.3.g352.
Full textDissertations / Theses on the topic "TYROSINE KINASE ASSAY"
Sinha, Tanay Kumar. "Validation and optimization of multiplexInSitu PLA for signalling pathway analysis." Thesis, Uppsala universitet, Institutionen för biologisk grundutbildning, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-450392.
Full textWortmann, Andreas. "In vitro and in vivo examination of the cell surface glycoprotein CDCP1." Thesis, Queensland University of Technology, 2010. https://eprints.qut.edu.au/40975/1/Andreas_Wortmann_Thesis.pdf.
Full textGuidi, Mònica. "Micro RNA-Mediated regulation of the full-length and truncated isoforms of human neurotrophic tyrosine kinase receptor type 3 (NTRK 3)." Doctoral thesis, Universitat Pompeu Fabra, 2009. http://hdl.handle.net/10803/7114.
Full textnervous system. Neurotrophin-3 binds preferentially to its high-affinity receptor
NTRK3, which exists in two major isoforms in humans, the full-length kinaseactive
form (150 kDa) and a truncated non-catalytic form (50 kDa). The two
variants show different 3'UTR regions, indicating that they might be differentially
regulated at the post-transcriptional level. In this work we explore how
microRNAs take part in the regulation of full-length and truncated NTRK3,
demonstrating that the two isoforms are targeted by different sets of microRNAs.
We analyze the physiological consequences of the overexpression of some of the
regulating microRNAs in human neuroblastoma cells. Finally, we provide
preliminary evidence for a possible involvement of miR-124 - a microRNA with no
putative target site in either NTRK3 isoform - in the control of the alternative
spicing of NTRK3 through the downregulation of the splicing repressor PTBP1.
Las neurotrofinas y sus receptores constituyen una familia de factores cruciales
para el desarrollo del sistema nervioso. La neurotrofina 3 ejerce su función
principalmente a través de una unión de gran afinidad al receptor NTRK3, del cual
se conocen dos isoformas principales, una larga de 150KDa con actividad de tipo
tirosina kinasa y una truncada de 50KDa sin dicha actividad. Estas dos isoformas
no comparten la misma región 3'UTR, lo que sugiere la existencia de una
regulación postranscripcional diferente. En el presente trabajo se ha explorado
como los microRNAs intervienen en la regulación de NTRK3, demostrando que las
dos isoformas son reguladas por diferentes miRNAs. Se han analizado las
consecuencias fisiológicas de la sobrexpresión de dichos microRNAs utilizando
células de neuroblastoma. Finalmente, se ha estudiado la posible implicación del
microRNA miR-124 en el control del splicing alternativo de NTRK3 a través de la
regulación de represor de splicing PTBP1.
Javier, Fatima Raezelle Santos. "STRUCTURAL AND FUNCTIONAL STUDIES OF THE EFFECTS OF PHOSPHORYLATION ON EPHRIN RECEPTOR TYROSINE KINASE, EPHA2." Case Western Reserve University School of Graduate Studies / OhioLINK, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=case1523027075371687.
Full textHughes, Stephen Bernard. "Development of real-time reverse transcription polymerase chain reaction assays to quantify insulin-like growth factor-1 receptor and insulin receptor expression in equine tissue." Diss., University of Pretoria, 2011. http://hdl.handle.net/2263/31135.
Full textDissertation (MMedVet)--University of Pretoria, 2011.
Production Animal Studies
Unrestricted
Galvan, Barbara. "Part I, highly sensitive hybridization assays for prostate-specific antigen mRNA based on time-resolved fluorescence and bioluminescence, Part II, fluorometric and time-resolved immunofluorometric assays for protein-tyrosine phosphatase and kinase activity." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1996. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/NQ30283.pdf.
Full textFiorini, Zeno. "IMMOBILIZED KINASE ACTIVITY BIOSENSORS FOR ABL KINASE IN CHRONIC MYELOID LEUKEMIA." Doctoral thesis, 2016. http://hdl.handle.net/11562/939238.
Full textChronic Myelogenous Leukemia (CML) is a blood cancer that affects each yearmore than 4500 patients in USA and more than 7500 in Europe. CML is caused byan acquired chromosomal rearrangement that results in the creation of BCR-ABL1, an abnormally active kinase. The uncontrolled activity of this kinasedetermines the accumulation of immature myeloid cells and the reduction of redblood cells and platelets in the blood stream. These changes compromise thefunction of immune system, oxygen delivery and coagulation. This diseaseremains often silent for many years in a so-called chronic phase (CP), but if leftuntreated, it proceeds to the more aggressive and least treatable accelerating(AP) and blastic phases (BP). Intervening with an effective therapeutic regimenin the shortest time possible is therefore of paramount importance.The standard clinical approach prescribes the detection of BCR-ABL1 kinasedomain mutations only in patients with an inadequate initial response to TKIs(primary resistance). The lack of initial response can be detected only after aminimum of 3-12 months from the diagnosis.The ability to understand how patients respond to drugs at diagnosis with asimple analysis of peripheral blood would help clinicians to prescribe morepatient-tailored treatments decreasing the insurgence of future drug resistance.The test assay we are proposing is based on an immobilized syntheticallyoptimized peptide with a high specificity for BCR-ABL1. The test uses antibodiesto detect the occurred peptide phosphorylation from appropriately preparedperipheral blood or bone marrow cell lysates.
(5930141), Minervo Perez. "HIGH-THROUGHPUT IDENTIFICATION OF ONCOGENIC TYROSINE KINASE SUBSTRATE PREFERENCES TO IMPROVE METHODS OF DETECTION." Thesis, 2021.
Find full textSousa, Bárbara Beatriz da Costa Botelho. "CRYSTAL STRUCTURE OF BONE MARROW TYROSINE KINASE FROM CHROMOSOME X WITH COVALENT LIGANDS." Master's thesis, 2018. http://hdl.handle.net/10362/70422.
Full textLamont, F. R., D. C. Tomlinson, Patricia A. Cooper, Steven D. Shnyder, J. D. Chester, and M. A. Knowles. "Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo." 2011. http://hdl.handle.net/10454/6061.
Full textBook chapters on the topic "TYROSINE KINASE ASSAY"
Sahal, Dinkar, Shu-Lian Li, and Yoko Fujita-Yamaguchi. "[5] Solid-phase protein-tyrosine kinase assay." In Methods in Enzymology, 90–98. Elsevier, 1991. http://dx.doi.org/10.1016/0076-6879(91)00129-k.
Full textKruljac‐Letunic, Anamarija, and Andree Blaukat. "Assay and Functional Properties of the Tyrosine Kinase Pyk2 in Regulation of Arf1 Through ASAP1 Phosphorylation." In Methods in Enzymology, 411–22. Elsevier, 2005. http://dx.doi.org/10.1016/s0076-6879(05)04036-x.
Full textPike, Linda J. "[33] Assay of growth factor-stimulated tyrosine kinases using synthetic peptide substrates." In Peptide Growth Factors - Part A, 353–62. Elsevier, 1987. http://dx.doi.org/10.1016/s0076-6879(87)46036-9.
Full textRijksen, Gert, Brigit A. Van Oirschot, and Gerard E. J. Staal. "[6] Nonradioactive assays of protein-tyrosine kinase activity using anti-phosphotyrosine antibodies." In Methods in Enzymology, 98–107. Elsevier, 1991. http://dx.doi.org/10.1016/0076-6879(91)00130-o.
Full textRacker, Efraim. "[7] Use of synthetic amino acid polymers for assay of protein-tyrosine and protein-serine kinases." In Methods in Enzymology, 107–11. Elsevier, 1991. http://dx.doi.org/10.1016/0076-6879(91)00131-f.
Full textDosquet, Hugo, Virginie Neirinckx, Max Meyrath, May Wantz, Serge Haan, Simone P. Niclou, Martyna Szpakowska, and Andy Chevigné. "Nanoluciferase-based complementation assays to monitor activation, modulation and signaling of receptor tyrosine kinases (RTKs)." In Methods in Enzymology. Elsevier, 2022. http://dx.doi.org/10.1016/bs.mie.2022.09.002.
Full textConference papers on the topic "TYROSINE KINASE ASSAY"
Deshpande, Sudhir S., I. Mineyev, and John C. Owicki. "Robust versatile tyrosine kinase assay for HTS in drug discovery." In BiOS '99 International Biomedical Optics Symposium, edited by Gerald E. Cohn and John C. Owicki. SPIE, 1999. http://dx.doi.org/10.1117/12.346748.
Full textLi, Chun-Qi. "Abstract LB-192:In vivozebrafish tyrosine kinase assay for anti-cancer drug screening." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-lb-192.
Full textKawai, M., Y. Torikoshi, M. Notoya, K. Gohda, NT Ueno, and H. Ishihara. "P5-13-02: Prediction of Dasatinib Sensitivity of Breast Cancer Based on a Novel Tyrosine Kinase-Activity Profiling Assay." In Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-p5-13-02.
Full textKawahata, Wataru, Tokiko Asami, and Masaaki Sawa. "Abstract C93: The design and synthesis of a novel fluorogenic probe targeting inactive forms of Burton's tyrosine kinase for high-throughput binding assay." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011; San Francisco, CA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1535-7163.targ-11-c93.
Full textAsami, Tokiko, Wataru Kawahata, and Masaaki Sawa. "Abstract C94: A novel binding assay to identify inhibitors that bind to inactive forms of Bruton's tyrosine kinase based on fluorescence resonance energy transfer." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011; San Francisco, CA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1535-7163.targ-11-c94.
Full textKong, Say Li, Huipeng Li, Dave Ruff, Joyce An Yi Tai, Elise T. Courtois, Huay Mei Poh, Dawn Pingxi Lau, et al. "Abstract 3153: Transcriptome differences in tyrosine kinase inhibitor-resistant clones ofEGFR-mutant lung cancer using a new microfluidic assay for concurrent single-cell RNA and targeted DNA sequencing." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-3153.
Full textSmith, Matthew A., Richard Hall, Kate Fisher, Ann Chen, and Eric B. Haura. "Abstract B27: Proximity ligation assays as biomarkers for receptor tyrosine kinase activity in lung tumors." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-b27.
Full textHallis, Tina, Connie Lebakken, Laurie Reichling, Jason Ellefson, Coby Carlson, Spencer Hermanson, Kun Bi, and Steve Riddle. "Abstract 3881: BacMam-enabled biochemical and cellular assays to assess inhibitors of full-length receptor tyrosine kinases." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3881.
Full text